PolyPid Ltd reports results for the quarter ended September 30 - Earnings Summary

• PolyPid Ltd PYPD.OQ reported quarterly adjusted earnings of $1.22​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-3.40. The mean expectation of four analysts for the quarter was for a loss of 100 cents per share. Wall Street expected results to range from $-1.12 to -88 cents per share.

• Reported revenue was zero​; analysts expected zero.

• PolyPid Ltd's reported EPS for the quarter was $1.22​.

• The company reported quarterly net income of $7.76 million.

• PolyPid Ltd shares had risen by 1.7% this quarter and lost 7.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 11.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for PolyPid Ltd is 12.00

This summary was machine generated from LSEG data November 13 at 03:25 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)